August 29, 2018


Media & events


Lyndra Therapeutics Achieves Critical Milestones Despite COVID-19 Headwinds

June 9, 2020
Lyndra Therapeutics Achieves Critical Milestones Despite COVID-19 Headwinds Örn Almarsson named Chief Technology Officer   Phase I trial for ultra-long-acting oral...
Read More
1 2 3 18


  • A once-a-month oral contraceptive
    A once-a-month oral contraceptive
1 2 3 6
A once-a-month oral contraceptive

Science Translational Medicine  04 Dec 2019:
Vol. 11, Issue 521, eaay2602
DOI: 10.1126/scitranslmed.aay2602
Categories :
URL : View Project


Lyndra Named as Scrip Award Finalist in Two Categories

Happy to announce our ultra-long acting oral dosage form has been named a finalist for the Scrip MSD Innovation Award, and our co-founder Amy Schulman has been named a finalist in the Executive of the Year category!


Amy Schulman, Lyndra Co-founder and CEO, honored on 2019 PharmaVOICE 100

“Amy’s fearless approach to create durable value and change the trajectory of compliance for some of most difficult to treat diseases —  Alzheimer’s disease, HIV, opioid use disorder, and schizophrenia — are just a couple of the reasons she has been identified as one of the 100 most inspiring people in the life-sciences industry,” says Taren Grom, editor, PharmaVOICE


2019 Xconomy Awards Finalist in Startup Category

We are honored to be named a finalist for the Awards in the category for our work making daily pills a thing of the past.



Lyndra Presents @ BIO International

Join us on Thursday, June 5th, at 5pm when Andrew Bellinger, our CSO, presents our 2019 Company Update at BIO International, Philadelphia Convention Center, Theater 4

2019 BIO International